Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
IAI climate change report
The International Aluminium Institute (IAI) recently commissioned Climate Risk Institute (CRI) and Risk Sciences International (RSI) to produce a series of informational tools evaluating and…
Quinolones and risk of acute liver failure
Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…
RSI launches Global Risk Census
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
Cell phones and cancer
Drs. Daniel Krewski and Franco Momoli recently contributed to an environmental research paper entitled: Cell phone use and the risk of glioma: are case-control study…